By ICR | Podcast
Sometimes abstract thinking that can lead to real breakthroughs. The knowledge and innovative thinking of today’s guests led to an life-changing solution to an ongoing 75-year puzzle.
Today we sit down with David Katz and Robert Jacks; Chief Scientific Officer, and President & CEO, of Sparrow Pharmaceuticals, respectively. Sparrow has come up with a groundbreaking way to help patients who need steroid treatments.
Robert was previously President & CEO of Indalo Therapeutics, a clinical-stage biotech company developing therapeutics for serious fibrotic diseases, and President, CFO, and Co-Founder of Symbiomix Therapeutics, which was sold after achieving NDA approval for Solosec®. Robert began his career in finance and product development at Pfizer, where he last worked as the Director of Business Development for Oncology and Infectious Diseases.
Prior to Sparrow, David Katz was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He has published over 50 peer-reviewed scientific papers.
If you have questions about the show, or have a topic in mind you’d like discussed in future episodes, email our producer, firstname.lastname@example.org.